<p>Tuznue is a cancer medicine used to treat the following conditions:</p><ul><li>early breast cancer (when the cancer has spread within the breast or to the lymph nodes [‘glands’] under the arm but not to other parts of the body). It is used after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable. It can also be used earlier in treatment, in combination with chemotherapy. For cancers that are locally advanced (including those that are inflammatory) or tumours more than 2 cm wide, Tuznue is used before surgery in combination with chemotherapy and then again after surgery on its own;</li><li>metastatic breast cancer (cancer that has spread to other parts of the body). It is used on its own when other treatments have not worked or are not suitable. It is also used in combination with other cancer medicines: paclitaxel or docetaxel, or with another type of medicine called an aromatase inhibitor;</li><li>metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or fluorouracil (other cancer medicines).</li></ul><p>Tuznue can only be used when the cancer overexpresses HER2. This means that the cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.</p><p>Tuznue contains the active substance trastuzumab and is a biological medicine. It is a ‘biosimilar medicine’. This means that Tuznue is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Tuznue is Herceptin.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p><strong>Metastatic breast cancer (MBC)</strong></p><p>For the treatment of adult patients with HER2-positive MBC:</p><ul><li>as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy unless patients are unsuitable for these treatments.</li><li>in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable</li><li>in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease</li><li>in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab </li></ul><p><strong>Early breast cancer (EBC)</strong></p><p>For the treatment of adult patients with HER2-positive EBC:</p><ul><li>following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)</li><li>following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.</li><li>in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.</li><li>in combination with neoadjuvant chemotherapy followed by adjuvant HD201 therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter. </li></ul><p>HD201 should only be used in patients with MBC or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.</p><p><strong>Metastatic gastric cancer (MGC)</strong></p><p>In combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.</p><p>HD201 should only be used in patients with MGC whose tumours have HER2 overexpression as defined by Immunohistochemistry (IHC) 2+ and a confirmatory silver-enhanced in situ hybridisation (SISH) or fluorescence in situ hybridisation (FISH) result, or by an IHC 3+ result. Accurate and validated assay methods should be used.</p></div>
Therapeutic Area (MeSH)
ATC Code
L01FD01
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| trastuzumab | N/A | trastuzumab |
EMA Name
Tuznue
Medicine Name
Tuznue
Aliases
N/ANo risk management plan link.
